The indolent systemic mastocytosis treatment market size is projected to be worth USD 437.4 million in 2023. The market is likely to surpass USD 797.8 million by 2033 at a CAGR of 6.2% during the forecast period.
A rare condition known as indolent systemic mastocytosis (ISM) is characterized by an aberrant buildup of mast cells in a variety of tissues and organs. The market for treating indolent systemic mastocytosis has a historical outlook that takes into account developments in both medical knowledge and the creation of therapeutic choices.
There were few available treatments for indolent systemic mastocytosis. Relief of symptoms and avoiding situations that can activate mast cells and release mediators were the main goals of treatment. The foundation of treatment was supportive care, which included antihistamines and drugs to manage symptoms like itching and flushing.
Other Drivers Propelling the Demand for Indolent Systemic Mastocytosis Treatment include:
Challenges for Companies /Manufacturers in the Indolent Systemic Mastocytosis Treatment Market:
Opportunities in the Indolent Systemic Mastocytosis Treatment Industry:
Latest Trends in the Indolent Systemic Mastocytosis Treatment Market:
| Attributes | Details |
|---|---|
| Indolent Systemic Mastocytosis Treatment Market Size (2023) | USD 437.4 million |
| Indolent Systemic Mastocytosis Treatment Market Projected Size (2033) | USD 797.8 million |
| Value CAGR (2023 to 2033) | 6.2% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
From 2017 to 2022, the global indolent systemic mastocytosis (ISM) treatment market experienced a CAGR of 6.0%, reaching a market size of USD 437.4 million in 2023.
From 2017 to 2022, ISM used to have few therapy choices that were primarily symptomatic in nature. The symptoms of skin lesions, gastrointestinal problems, and anaphylactic reactions were frequently treated with antihistamines, corticosteroids, and drugs to suppress allergic reactions. But these medicines were frequently insufficient for long-term illness management.
Future Forecast for Indolent Systemic Mastocytosis Treatment Industry:
Looking ahead, the global indolent systemic mastocytosis treatment industry is expected to rise at a CAGR of 6.7% from 2023 to 2033. According to the anticipated view, ISM treatment will increasingly emphasize personalized medicine.
By taking into account the unique genetic changes and illness characteristics of each patient, genetic profiling and biomarker discovery can assist in customizing therapy options. By offering more specialized and efficient treatments, this strategy may enhance treatment outcomes.
| Country | The United States |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 179.6 million |
| CAGR % 2023 to End of Forecast (2033) | 4.8% |
The indolent systemic mastocytosis treatment industry in the United States is expected to reach a market size of USD 179.6 million by 2033, expanding at a CAGR of 4.8%.
The increasing awareness and diagnosis of the disease, which has led to a greater demand for effective treatments. Also, the development of new innovative therapies has also contributed to the growth of the market.
| Country | The United Kingdom |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 22.8 million |
| CAGR % 2023 to End of Forecast (2033) | 4.0% |
The indolent systemic mastocytosis treatment industry in the United Kingdom is expected to reach a market value of USD 22.8 million, expanding at a CAGR of 4.0% during the forecast period.
The United Kingdom market is projected to growth of the market due to the advanced infrastructure and a strong focus on research and development has also played a role in growth of market in UK There is also growing trend towards personalized medicine wherein treatments are tailored to individual patient needs.
| Country | China |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 57.5 million |
| CAGR % 2023 to End of Forecast (2033) | 5.5% |
The indolent systemic mastocytosis treatment industry in China is anticipated to reach a market size of USD 57.5 million, moving at a CAGR of 5.5% during the forecast period.
The indolent systemic mastocytosis treatment industry in China is expected to grow prominently due to the ongoing collaboration and partnerships between domestic and international pharmaceutical companies, also, it is expected that there will be an increase in research and development activities leading to more efficient and affordable indolent systemic mastocytosis treatments.
| Country | Japan |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 40.5 million |
| CAGR % 2023 to End of Forecast (2033) | 5.3% |
The indolent systemic mastocytosis treatment industry in Japan is estimated to reach a market size of USD 40.5 million by 2033, thriving at a CAGR of 5.3%. The availability of experienced and qualified healthcare professionals has significantly contributed to the growth of indolent systemic mastocytosis treatment.
| Country | South Korea |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 25.2 million |
| CAGR % 2023 to End of Forecast (2033) | 4.9% |
The indolent systemic mastocytosis treatment industry in South Korea is expected to reach a market size of USD 25.2 million, expanding at a CAGR of 4.9% during the forecast period.
The market in South Korea is forecasted to witness growth due to the increasing number of pharma companies establishing their presence in South Korea may contribute to the sustained growth of the indolent systemic mastocytosis treatment.
The Mast Cell Stabilizer (Cromolyn Sodium) is expected to dominate the indolent systemic mastocytosis treatment industry with a CAGR of 5.9% from 2023 to 2033.
Cromolyn sodium is commonly used in the treatment of ISM to manage symptoms associated with mast cell activation, such as skin rash, itching, gastrointestinal disturbances, and systemic symptoms like fatigue and bone pain.
By stabilizing mast cells and preventing the release of inflammatory mediators, Cromolyn sodium helps alleviate these symptoms, improving the quality of life for patients with ISM.
The prescription drugs segments are expected to dominate the indolent systemic mastocytosis treatment industry with a CAGR of 6.6% from 2023 to 2033. Prescription drugs are essential for managing the symptoms and complications associated with ISM.
These drugs help control mast cell activation and reduce the release of inflammatory mediators, thereby alleviating symptoms such as skin rash, itching, gastrointestinal disturbances, and systemic symptoms like fatigue and bone pain.
By providing effective symptom relief, prescription drugs improve the quality of life for patients with ISM, driving the demand for treatment options and contributing to market growth.
The oral route of administration segments are expected to dominate the indolent systemic mastocytosis treatment industry with a CAGR of 5.3% from 2023 to 2033. The oral route of administration offers convenience and ease of use for patients with ISM.
Oral medications can be self-administered at home without the need for healthcare professionals or medical facilities. This convenience improves patient compliance, as they can adhere to their prescribed treatment regimen more easily. As a result, the demand for oral medications increases, contributing to market growth.
The hospital pharmacies segment is expected to dominate the indolent systemic mastocytosis treatment industry with a CAGR of 5.5% from 2023 to 2033. Hospital pharmacies are responsible for dispensing medications prescribed for ISM patients.
They ensure the availability of necessary medications, including mast cell stabilizers, targeted therapies, and other medications used in ISM treatment. The efficient and timely dispensing of these medications by hospital pharmacies supports patient access to treatment and contributes to market growth.
The indolent systemic mastocytosis treatment sector is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must employ smart techniques.
Key Strategies Used by the Participants
To produce innovative goods that increase efficacy, dependability, and cost-effectiveness, businesses make significant investments in research and development. Product innovation enables companies to stand out from the competition while also meeting the shifting needs of their customers.
Key industry leaders frequently develop strategic partnerships and collaborations with other companies in order to harness their strengths and increase their market reach. Companies might also gain access to new technology and markets through such agreements.
The indolent systemic mastocytosis treatment sector is expanding rapidly in emerging regions such as China and India. Key firms are enhancing their distribution networks and developing local manufacturing facilities to increase their presence in these areas.
Mergers and acquisitions are frequently used by key players in the indolent systemic mastocytosis treatment business to consolidate their market position, extend their product range, and gain access to new markets.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Key Developments in the Indolent Systemic Mastocytosis Treatment Market:
In May 2023, The USA Food and Drug Administration (FDA) has authorised AYVAKIT® (avapritinib) for the treatment of people with indolent systemic mastocytosis (ISM), according to a statement from Blueprint Medicines Corporation. The first and only medication licenced to treat ISM is now available to all patients in the United States.
The market is valued at USD 437.4 million in 2023.
GSK Plc and Pfizer Inc. are the leading market players.
The hospital pharmacies are likely to remain preferred through 2033.
Players opt for mergers, collaborations, and acquisitions.
The United States, the United Kingdom, and China dominate the global market.
Explore Therapy Area Insights
View Reports
Indolent Systemic Mastocytosis treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
